Isolation of Candida auris in Clinical Specimens.

Methods Mol Biol

Medical Mycology Unit, Department of Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.

Published: June 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Candida auris is a multidrug-resistant yeast causing healthcare-associated outbreaks of blood stream infections worldwide. Currently, C. auris isolation and identification is complicated by issues such as misidentification and long turnaround time associated with application of commonly used diagnostic tools. Based on phenotypic characteristics, differentiation of C. auris from related Candida haemulonii complex spp. is problematic. Candida auris can be misidentified using biochemical-based systems such as VITEK 2 YST, API 20C, BD Phoenix yeast identification system, and MicroScan. C. auris growth at 42 °C and in the presence of 10% NaCl helps in presumptive identification of this yeast from related Candida haemulonii complex spp. A new CHROMagar™ Candida Plus agar is an excellent alternative to current conventional mycological media for the screening of patients colonized/infected with Candida auris. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) can differentiate C. auris from other Candida species, but not all the reference databases included in MALDI-TOF devices allow for detection. Currently, accurate identification of C. auris can be performed using the updated FDA-approved libraries or "research use-only" libraries. Molecular techniques have greatly enhanced the diagnosis of C. auris. Sequencing of rDNA genetic loci, namely, internal transcribed spacer and D1/D2 region of large subunit (LSU), and PCR/qPCR assays has successfully been applied for identification of C. auris. Real-time PCR assays bear incomparable potential of being the most efficient tool for high-throughput screening of surveillance samples. If properly validated, they can deliver the diagnostic result within several hours, since the DNA can be isolated directly from the patient specimen without the need of obtaining a colony. In this chapter we detailed the isolation of Candida auris from various clinical specimens and its currently available identification methods and hitches.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-0716-2417-3_1DOI Listing

Publication Analysis

Top Keywords

candida auris
20
auris
12
isolation candida
8
auris clinical
8
clinical specimens
8
candida
8
auris candida
8
candida haemulonii
8
haemulonii complex
8
complex spp
8

Similar Publications

emerged in Chicago, IL, USA, in 2016 and has since become endemic. We used whole-genome sequencing (WGS) of 494 isolates, epidemiologic metadata and patient transfer data to describe the transmission of among Chicago healthcare facilities between 2016 and 2021. In total, 99% of isolates formed a single clade IV phylogenetic lineage, suggesting a single introduction.

View Article and Find Full Text PDF

Echinocandins, which target the fungal β-1,3-glucan synthase (Fks), are essential for treating invasive fungal infections, yet resistance is increasingly reported. While resistance typically arises through mutations in Fks hotspots, emerging evidence suggests a contributing role of changes in membrane sterol composition due to mutations. Here, we present a clinical case of () in which combined mutations in and , but not alone, appear to confer echinocandin resistance.

View Article and Find Full Text PDF

Introduction: Candida auris is a yeast that has a high mortality rate in critically ill patients and is resistant to many antifungal agents enhancing its clinical importance. Our study identifies the risk factors for C. auris invasive infection, antifungal susceptibility, and outcomes.

View Article and Find Full Text PDF

Candidemia, a common hospital-acquired bloodstream infection, is associated with significant mortality, particularly in cases involving (). The Middle East, including Saudi Arabia, has seen an increasing number of invasive infections. This review examines the epidemiology, risk factors, antifungal susceptibility, clinical manifestations, and mortality associated with , based on published literature from Saudi Arabia.

View Article and Find Full Text PDF

Forty years of global research on WHO's four critical priority fungal pathogens: Advances and prospects.

J Infect Public Health

August 2025

Infection Control Center, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, China; National Clinical Research Center for Geriatric Disorders (XiangYa Hospital), Changsha, Hunan Province 410008, China; Superbugs and Multidrug Resistant Microbes Infection Control Research Ce

Background: On October 25, 2022, the World Health Organization (WHO) released its first Fungal Priority Pathogen List (FPPL), classifying Cryptococcus neoformans (C. neoformans), Candida auris (C. auris), Aspergillus fumigatus (A.

View Article and Find Full Text PDF